Skip to main content
. Author manuscript; available in PMC: 2013 Dec 15.
Published in final edited form as: Cancer Res. 2012 Oct 22;72(24):6447–6456. doi: 10.1158/0008-5472.CAN-12-0193

Fig. 3. Systemic shIDO-ST treatment suppresses tumor growth in the absence of functional adaptive immunity.

Fig. 3

A, Depleting antibody specific for CD4+, CD8+, or NK subsets were administered i.p. into B16F10 tumor-bearing mice (n=3). Data represents cell populations in blood 24 hours after i.p. injection. B and C, B16F10 tumor-bearing C57BL/6 mice in B or IDO-KO mice in C (n=4) were treated (arrows) with shIDO-ST. Antibody depletion of CD8+, CD4+, and NK immune subsets began 2d after the first shIDO-ST inoculation, with maintenance depletions every 3d. D, B16F10 tumor-bearing RAG1-KO mice (n=4) were treated (arrows) with shScr-ST or shIDO-ST and tumor volume was measured longitudinally. *P<0.05 by Student’s t test.